(2-Pack) SEMAX – 10mg
Related Products
Peer-Reviewed Literature
Related Studies
Peer-Reviewed Literature
Related Studies
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial)
New England Journal of Medicine
Landmark trial of 17,604 patients showed semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% in non-diabetic patients with obesity over 39.8 months.
Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes (SUSTAIN-6)
New England Journal of Medicine
104-week trial in 3,297 high-risk T2DM patients showed semaglutide reduced composite MACE by 26% versus placebo — establishing cardiovascular benefit for GLP-1 receptor agonists.
Oral Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes (PIONEER 6)
New England Journal of Medicine
Demonstrated cardiovascular safety of oral semaglutide 14 mg daily versus placebo in 3,183 high-risk T2DM patients, with trend toward all-cause mortality reduction.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
New England Journal of Medicine
68-week trial of 1,961 adults showed semaglutide 2.4 mg weekly achieved 14.9% mean body weight loss versus 2.4% with placebo, establishing landmark weight management efficacy.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
New England Journal of Medicine
In 3,297 patients with T2D, semaglutide reduced major adverse cardiovascular events by 26% versus placebo over 2.1 years (HR 0.74), driven by 39% stroke reduction and 26% nonfatal MI reduction.
Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Nature Medicine
Participants receiving semaglutide 2.4 mg weekly maintained 15.2% body weight loss at 104 weeks, with significant improvements in cardiometabolic risk factors including waist circumference and HbA1c.